New Chairman David Chiswell set to support SENISCA’s rapid development of its senotherapeutic platform.
SENISCA, a UK-based biotech developing RNA based therapeutics to reverse cellular senescence and treat age-related disease, has today announced the appointment of Dr David Chiswell PhD, OBE as Chairman of the Board.
Longevity.Technology: SENSICA was spun out of the University of Exeter and is developing a portfolio of proprietary senotherapeutics, that target cell senescence. The company’s oligonucleotide-based therapy modulates RNA splicing, increasing regulatory proteins and improving molecular resilience – in effect, reversing senescence.
SENISCA has an initial focus on skin aging; not only is the skin the largest organ, but it is the first to display the signs of aging in a way that can be directly observed in a non-invasive and quantifiable way. SENISCA’s platform technology also has broad applicability for multiple age-related diseases including those of the eyes, lungs, joints and brain.
Dr David Chiswell is a seasoned biotech executive, with extensive experience in the development of early-stage biotechnology companies over 30 years in the industry. He joins the SENISCA Board having co-founded Cambridge Antibody Technology (CAT) in 1990 and served as its CEO from 1996 to 2002, taking CAT onto both the London Stock Exchange and Nasdaq. Chiswell currently serves as Chairman of Epsilogen and is a director of Avillion Bond 2 Development 2 GP and the Schiehallion Fund (LSE:MNTN).
As well as serving as Chairman on the boards of various biotechs, including Albireo, Arrow and Sosei, Chiswell was also formerly Chairman of the UK BioIndustry Association, and his contributions to the industry were recognized with the awarding of an OBE in 2006.
Dr Sarah Cole, CEO of SENISCA, commented: “We are honoured to welcome Dr. Chiswell to our Board at SENISCA. His deep knowledge and expertise in the biotechnology sector – particularly in early-stage companies, combined with his strategic expertise will be crucial as we continue our evolution towards becoming a clinical stage biotechnology company developing novel senotherapeutics to treat age-related disease. Our ability to attract someone of David’s calibre speaks volumes about the quality of our science and the strong foundational work our team has undertaken.”
Dr David Chiswell, Chairman of the Board of SENISCA commented: “SENISCA is a revolutionary company with the potential to transform the landscape of senotherapeutic treatments. I am thrilled to be joining the Company as Chairman, and I look forward to collaborating with the Board and leadership team as SENISCA progresses into the next stage of its development.”
